CUA Educational Content

Evolution of Radionuclide Therapy in Prostate Cancer

Speakers: Neil Fleshner & Sebastien Hotte

Objectives

By participating in this learning program, healthcare providers can expect to gain an understanding of:

  • Understand the current role of radionuclide therapy in managing prostate cancer patients and discuss strategies for sequencing
  • Explore the latest clinical data on radionuclide therapies in prostate cancer including emerging treatment strategies
  • Discuss the future direction of radionuclide therapy in prostate cancer, including the development of next-generation molecules and combination therapies
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

This program has received financial support from Bayer in the form of an educational grant.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy